![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LJ Murphey and GD Olsen
Department of Pharmacology, School of Medicine, Oregon Health Sciences University, Portland.
Morphine-6-beta-D-glucuronide (M6G) is a metabolite of morphine with opioid activity in adults. No data are available, however, on the developmental pharmacology of M6G including investigation of the respiratory effects of M6G in the neonate. A randomized, placebo- controlled study comparing the time-action, dose-response and potency of the respiratory effects of M6G to morphine was done using a nonanesthetized neonatal guinea pig model and a noninvasive computerized plethysmograph technique. Respiration was measured while the neonate breathed room air followed by 5% CO2 in air. M6G (0.5-5.0 mg/kg) and morphine (1.5-15 mg/kg) administered subcutaneously decreased ventilation in 3-, 7- and 14-day-old neonatal guinea pigs given a 5% CO2 challenge. During CO2 inhalation, time-to-peak action for M6G occurred 21 min later than for morphine. At maximal ventilatory depression on day 3, a dose of 1.5 mg/kg morphine or M6G decreased minute ventilation while breathing 5% CO2 by 30% compared to placebo. Ventilation also decreased as a function of age in both placebo and drug-treated animals. The percent respiratory depression relative to placebo remained constant for a given dose of morphine as the neonate aged, but not for M6G, which increased in potency. M6G was equipotent to morphine on day 3 after birth, but was 8-fold more potent by day 7. This increase in potency persisted through day 14. The increased potency of M6G that accompanies aging may be caused by either a change in M6G disposition or a change in opioid receptors during development of the neonatal guinea pig.
This article has been cited by other articles:
|
|
 |
|
  E. L. A. van Dorp, R. Romberg, E. Sarton, J. G. Bovill, and A. Dahan Morphine-6-Glucuronide: Morphine's Successor for Postoperative Pain Relief? Anesth. Analg., June 1, 2006; 102(6): 1789 - 1797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Romberg, E. Sarton, L. Teppema, H. W. D. Matthes, B. L. Kieffer, and A. Dahan Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and {micro}-opioid receptor deficient mice Br. J. Anaesth., December 1, 2003; 91(6): 862 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Letrent, G. M. Pollack, K. R. Brouwer, and K. L.R. Brouwer Effects of a Potent and Specific P-Glycoprotein Inhibitor on the Blood-Brain Barrier Distribution and Antinociceptive Effect of Morphine in the Rat Drug Metab. Dispos., July 1, 1999; 27(7): 827 - 834. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Ohtani, H. Kotaki, K. Nishitateno, Y. Sawada, and T. Iga Kinetics of Respiratory Depression in Rats Induced by Buprenorphine and its Metabolite, Norbuprenorphine J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 428 - 433. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
